Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Endocarditis IV: Nursing Management

Endocarditis IV: Nursing Management

Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Endocarditis III: Medical Management

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

Factors Affecting the Risk of Infection

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Translated article] Expert Recommendations on Topical Therapy for Psoriasis from the Spanish Psoriasis Working Group (GPS).

Actas dermo-sifiliograficas·2025

Same author

Expert Recommendations on Topical Therapy for Psoriasis from the Spanish Psoriasis Working Group (GPS).

Actas dermo-sifiliograficas·2025

Same author

Atypical Molluscum Contagiosum in a Psoriatic Patient on Biological Therapy.

Actas dermo-sifiliograficas·2024

Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024

Same author

Atypical Molluscum Contagiosum in a Psoriatic Patient on Biological Therapy.

Actas dermo-sifiliograficas·2024

Same author

[Translated article] Immune-Mediated Skin Reactions to Tumor Necrosis α Inhibitors: A Review of 30 Cases.

Actas dermo-sifiliograficas·2023

Search research articles

Related Experiment Videos

[Etanercept and infections].

M Ribera¹, L Leal, J Luelmo

¹Servicio de Dermatología, Hospital Universitari de Sabadell, Corporació Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, España. miquel.ribera@uab.cat

Actas Dermo-Sifiliograficas

|May 25, 2010

Summary

This summary is machine-generated.

Tumor necrosis factor-alpha inhibitors (TNF-alpha) are effective psoriasis treatments but may slightly increase infection risk. Careful patient selection and monitoring are crucial for managing infections during TNF-alpha therapy.

Related Experiment Videos

Area of Science:

Immunodermatology
Pharmacology
Infectious Disease

Background:

Biological treatments, particularly TNF-alpha inhibitors, are established for psoriasis.
These therapies have shown significant efficacy and safety in clinical trials and post-marketing surveillance.

Observation:

Pharmacovigilance data indicate a slight rise in infections associated with TNF-alpha inhibitors.
Specific patient populations require careful risk assessment, including those with viral hepatitis (HCV, HBV), HIV, existing infections, or predisposing conditions like diabetes and hemodialysis.

Findings:

Management strategies for infectious risk in patients on etanercept or other anti-TNF agents are essential.
Discontinuation of treatment is recommended for serious infections, while mild infections warrant close monitoring and potential interruption based on clinical evolution.

Implications:

Etanercept demonstrates a favorable safety profile concerning infections when appropriate precautions are implemented.
Vigilance for tuberculosis and concurrent active infections is paramount during TNF-alpha inhibitor treatment to ensure patient safety.